Related Experiment Video
Updated: Jun 5, 2026
09:29
Assessing Cardiomyocyte Subtypes Following Transcription Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts
Published on: March 22, 2017
Gene expression in cardiac hypertrophy
1INSERM U127, Hôpital Lariboisiére, 75010 Paris, France.
Trends in Cardiovascular Medicine
|January 18, 2011
Summary
Cardiac hypertrophy, a heart enlargement from increased workload, is linked to human illness and death. Understanding modified gene regulation in hypertrophy is key to preventing heart failure progression.
Area of Science:
- Cardiology
- Molecular Biology
- Genetics
Background:
- Cardiac hypertrophy results from hemodynamic overload.
- It is a significant factor in human morbidity and mortality.
- Hypertrophy involves altered gene expression for functional adaptation.
Purpose of the Study:
- To analyze the changes in gene expression during cardiac hypertrophy.
- To investigate the regulatory mechanisms underlying these gene expression modifications.
- To understand the role of hypertrophy in the pathogenesis of heart failure.
Main Methods:
- Analysis of gene expression patterns in hypertrophied hearts.
- Investigation of molecular mechanisms controlling gene regulation.
- Correlation of gene expression changes with functional requirements.
Main Results:
- Cardiac hypertrophy involves quantitative and qualitative changes in gene expression.
- Gene regulation, not the genes themselves, is modified.
- These alterations aim to meet increased functional demands.
Conclusions:
- Understanding modified gene regulation in cardiac hypertrophy is crucial.
- This knowledge is essential for elucidating the role of hypertrophy in heart failure.
- Targeting regulatory mechanisms may offer therapeutic strategies.
Related Concept Videos
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
01:26Cellular Adaptation II: Hypertrophy
Hypertrophy is the increase in the size of individual cells, resulting in the enlargement of a tissue or organ. Unlike hyperplasia, which involves an increase in cell number, hypertrophy is characterized by an increase in cell volume. This process often occurs in response to higher functional demand or hormonal stimulation, leading to the production of more structural proteins and organelles, thereby enhancing the cells' work capacity.There are two primary types of hypertrophy: physiological...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...